Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

The trough concentration adapted infliximab treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3-7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases (IBD), with fewer flares than clinic-based dosing. We performed a follo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Gastroenterology and Hepatology 2018-08, Vol.16 (8), p.1276-1283.e1
Hauptverfasser: Pouillon, Lieven, Ferrante, Marc, Van Assche, Gert, Rutgeerts, Paul, Noman, Maja, Sabino, João, Vande Casteele, Niels, Gils, Ann, Vermeire, Séverine
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The trough concentration adapted infliximab treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3-7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases (IBD), with fewer flares than clinic-based dosing. We performed a follow-up analysis of study participants to explore the correlation between trough dosing strategy and mucosal healing, continued infliximab use, and rates of hospitalization, surgery, and steroid use.
ISSN:1542-3565